Eno, Genesis AI’s first general-purpose robot, is lifting a box from between two conveyor belts in a warehouse.  (Photo: Genesis AI)

Eno, Genesis AI’s first general-purpose robot, is lifting a box from between two conveyor belts in a warehouse.  (Photo: Genesis AI)

Genesis AI has raised $500m in its Series A funding round, at a valuation of $3.5bn. The Franco-American company now plans to manufacture and deploy Eno, its general-purpose robot, in factories, warehouses and laboratories. The funding round was announced on Tuesday 17 November.

A Series A round worth half a billion dollars. Genesis AI is skipping several of the usual stages of start-up funding to move directly from research to the prospect of industrial roll-out.

Premji Invest, Khosla Ventures and Eclipse co-led the round. Durable Capital Partners, T. Rowe Price Associates, Bpifrance, HSG, Nvidia, AMD Ventures, Zoom, Samsung Next and Ericsson are also participating. Eric Schmidt, Eric Yuan, Jerry Yang, Xavier Niel and Zach Kirkhorn have invested in a personal capacity.

Founded by Zhou Xian and Théophile Gervet, Genesis AI is developing Eno, a robot designed to perform a range of tasks rather than simply repeating a single operation. The company builds the hardware, software, artificial intelligence models and simulation tools itself, with a view to improving them in tandem.

The funding is to be used to finance data acquisition, model training and the recruitment of researchers and engineers. Genesis AI plans to initially deploy its robots in industry, logistics and laboratories. The hospitality and healthcare sectors, followed by consumer applications, would come next.

KKR joins Carlyle with $475m to buy shares

Litmus Music has secured approximately $475m in new funding from Carlyle and KKR to acquire music catalogues. The platform, founded in 2022 and still controlled by Carlyle, already manages $1.4bn in assets and over 100,000 copyright works and recordings.

Katy Perry, Randy Newman and Keith Urban are, indirectly, becoming financial assets. Their works are among the rights held by Litmus Music, a platform whose growth is based on the future revenue generated by the songs.

Carlyle Global Credit had established Litmus in 2022 alongside its management team, with an initial commitment of $500m in equity and debt. Four years on, Carlyle remains the majority shareholder but has welcomed KKR as a new strategic investor.

KKR invests primarily through Asset-Based Finance Partners II, an asset-backed credit fund. Carlyle utilises its Credit Opportunities strategy. The songs serve as an economic underpinning here: their future royalties are used to finance the acquisition of the catalogues.

Goldman Sachs leads the $280m raised by Payhawk

European expenditure management software firm Payhawk has raised $280m at a valuation of $2bn. EQT has acquired battery developer Flatiron Energy, Blue Sea has raised $800m for the healthcare sector, and Centerbridge has acquired Amplix. ICG is providing funding for the French network Chronos Dental, without taking a controlling stake.

Payhawk raises $280m without having fully utilised its previous funding round. Payhawk, which provides businesses with payment cards and expenditure management software, has announced a $280m Series C equity round. Goldman Sachs Alternatives’ Growth Equity arm is leading the round, which was completed on the basis of a $2bn valuation. The transaction remains subject to the usual regulatory approvals.

QED, Greenoaks, Lightspeed, Hedosophia and Bek Ventures are reinvesting. Galdana Ventures, Cogito Capital, Inveready and Invus are taking a stake in the company.

Payhawk claims to have achieved a positive cash flow in the third quarter and to have retained 70% of the funds raised in 2022. The company, which was founded in Sofia, operates in 33 countries.

EQT acquires a US battery portfolio totalling 24GWh

EQT has finalised the acquisition of Flatiron Energy from Hull Street Energy. Flatiron develops, builds and operates large-scale batteries connected to electricity grids in the eastern United States.

Its portfolio totals 24GWh, of which 6GWh is covered by long-term contracts and 2GWh is under construction. The price has not been disclosed.

The transaction is being carried out through the EQT Transition Infrastructure strategy and is due to be completed in the fourth quarter of 2026, subject to regulatory approvals. It is therefore still an agreement and not a completed acquisition.

Blue Sea exceeds its target, raising $800m for healthcare

Blue Sea Capital has closed its fourth fund with $800m in commitments. The fund manager had initially targeted $550m and had set a cap of $700m, which was subsequently raised. The fundraising campaign lasted four months.

This first Blue Sea fund, dedicated exclusively to the healthcare sector, targets companies with a valuation of up to $500m. The previous fund had raised nearly $620m.

Blue Sea reports that it completed four exits in 2026, representing a combined enterprise value of approximately $1.5bn.

Centerbridge acquires technology consultancy Amplix

Centerbridge Partners has acquired Amplix from Gemspring Capital. Amplix advises more than 3,500 companies on the selection, deployment and management of technologies, including cloud computing, cyber security, artificial intelligence and telecommunications.

Gemspring had owned the company since 2022. Amplix has made 15 acquisitions since then. The transaction is reported as having been completed, but the price and financial terms have not been disclosed.

ICG is providing funding to Chronos Dental without taking a controlling stake

ICG is providing a bespoke financing solution to Chronos Dental, a French group comprising 35 dental prosthetics laboratories, over 600 employees and more than 5,000 dentist clients. The exact amount and form of the financing have not been disclosed. The founders, Mathieu Carton and Manuel Moustaid, along with the denture technicians who are shareholders, will retain control. The funds are intended to finance acquisitions in France, European expansion and the digitisation of production. The transaction is therefore not a takeover of Chronos Dental by ICG.